Core Viewpoint - The company announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has proposed to be selected for the national centralized procurement of clarithromycin tablets and simvastatin tablets, with the procurement period extending until December 31, 2028 [1] Group 1 - The total sales revenue for the two products in 2024 is projected to be 38.99 million yuan, which accounts for 11.81% of the company's total revenue [1] - If the purchase and sales agreement is signed, it will expand the sales scale of the company [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has participated in the national centralized procurement for drugs whose agreements are expiring, with some products expected to be selected for procurement [1] Group 1: Procurement Participation - Zhejiang Beid Pharmaceutical has submitted applications for the national centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement selection were published by the procurement office on February 10, 2026, indicating that some products from Beid Pharmaceutical are likely to be selected [1] Group 2: Selected Products and Financial Impact - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets, both of which are included in the national medical insurance catalog [1] - For the year 2024, the sales revenue of Clarithromycin tablets is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue of Simvastatin tablets is projected to be 1.71 million yuan, representing 0.52% of the company's main business income during the same period [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are expected to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national organized centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement process, published by the procurement office on February 10, 2026, indicate that some of Beid Pharmaceutical's products are likely to be selected [1] - The products expected to be selected include Clarithromycin Tablets and Simvastatin Tablets, both of which are included in the national medical insurance catalog [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are proposed to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national centralized procurement of drugs as part of the first to eighth batches, excluding insulin [1] - The proposed selected products from Beid Pharmaceutical include Clarithromycin Tablets and Simvastatin Tablets, both of which are listed in the national medical insurance catalog [1]

Core Viewpoint - The company Sunflower announced that its subsidiary, Beid Pharmaceutical, is participating in the continuation procurement of drugs from the national organized procurement batches 1-8, with some products expected to be selected [1] Group 1: Selected Products - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets [1] - The procurement period for the selected products will last from the actual execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The sales revenue for Clarithromycin tablets in 2024 is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue for Simvastatin tablets is expected to be 1.71 million yuan, representing 0.52% of the company's main business income for the same period [1]

Group 1 - Company subsidiary Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.49 million yuan and late fees of about 10.74 million yuan, while Hainan Kangli Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.28 million yuan and late fees of about 11.71 million yuan, totaling around 65.22 million yuan [1][2] - The tax payment does not involve any administrative penalties and will be settled as required [1] - The tax arrears and late fees will be included in the company's 2025 profit and loss, expected to impact the net profit by 65.22 million yuan [2] Group 2 - Company subsidiary Tianfang Pharmaceutical Co., Ltd. received approval for the drug Clarithromycin Tablets, which passed the consistency evaluation for generic drug quality and efficacy [4][5] - Clarithromycin is used to treat infections caused by sensitive pathogens, with a market presence since 1991 [5][8] - The total investment in the Clarithromycin project is approximately 11.79 million yuan [7] - The domestic sales of Clarithromycin in public hospitals and grassroots medical institutions were about 407 million yuan in 2024, with the company's sales at approximately 2.83 million yuan [8]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for Tianfang Pharmaceutical, enhancing its product portfolio [1] - Clarithromycin Tablets are now positioned to compete in the market following the successful evaluation [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical sector [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval notification for Clarithromycin Tablets was issued by the National Medical Products Administration [1] - The drug has successfully passed the consistency evaluation of quality and efficacy, indicating its compliance with regulatory standards [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved drug, Clarithromycin, is indicated for the treatment of infections caused by sensitive pathogenic bacteria, including lower respiratory tract infections, upper respiratory tract infections, and skin and soft tissue infections [1]